ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1809 • ACR Convergence 2023

    Clinical Outcome and Antibody Responses Following the Surge of SARS-CoV-2 Omicron Infection Among Patients with Systemic Autoimmune Diseases

    Zhu Chen1, nan xiang1, Qian Wang1, Yuwei Li1, Huizhi Jin1, Guosheng Wang1, Xiaomei Li2, Tengchuan Jin1 and Wei Bao1, 1University of Science and Technology of China, Hefei, China, 2University of Science and Technology of China, Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Hefei, China

    Background/Purpose: The surge of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant Omicron infections has affected most Chinese residents at the end of 2022, including…
  • Abstract Number: 0995 • ACR Convergence 2023

    Rheumatoid Arthritis Early Diagnostic Clinic: A Web-based Referral Tool Serving Ethnic Minority Patients

    Mercedes Quinones1, Sharon Dowell2, Ilona Jileaeva3, Oshoze Kadiri3, Christopher Swearingen4 and Gail Kerr5, 1Washington DC VA Medical Center, Bethesda, MD, 2NEA Baptist Memorial Hospital, Jonesboro, AR, 3Howard University, Washington, DC, 4Biosplice Therapeutics, Inc., San Diego, CA, 5Washington DC VAMC/Georgetown and Howard Universities, Washington, DC

    Background/Purpose: Rheumatoid Arthritis (RA) data indicate a "window of opportunity" during which DMARD therapy is most effective in achieving early and sustained remission, hence expedited…
  • Abstract Number: 1841 • ACR Convergence 2023

    Clinical Trial Perceptions Among Male Patients with Systemic Lupus Erythematosus (SLE): Georgians Organized Against Lupus (GOAL) Cohort

    Hilton Mozee1, Charmayne Dunlop-Thomas1, Gaobin Bao1, Kim Schofield2, Jessica Williams3 and S. Sam Lim1, 1Emory University, Atlanta, GA, 2Georgia State Rep. HD 63, Atlanta, GA, 3Emory University School of Medicine, Atlanta, GA

    Background/Purpose: Minority patients are disproportionately affected by SLE. Yet, they are underrepresented in SLE clinical trials compared to White patients. Specifically, patients that identify as…
  • Abstract Number: 1364 • ACR Convergence 2023

    Both Low and High 25(OH)-Vitamin D Levels Increase Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus

    Nima Madanchi1, Andrea Fava2, Daniel Goldman3, Larry Magder4, Rebecca Jacobson1 and Michelle Petri3, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 4University of Maryland, Baltimore, MD

    Background/Purpose: We evaluated the role of maternal 25(OH)-vitamin D in adverse pregnancy outcomes in systemic lupus erythematosus (SLE). Methods: We used a longitudinal cohort that…
  • Abstract Number: 1033 • ACR Convergence 2023

    The Detection of Subclinical Joint Inflammation by Thermal and Ultrasound Imaging at the Metacarpophalangeal Joints in Patients with Rheumatoid Arthritis

    York Kiat Tan1 and Gek Hsiang Lim2, 1Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, 2Health Services Research Unit, Singapore General Hospital, Singapore, Singapore

    Background/Purpose: While magnetic resonance imaging and ultrasound (US) imaging have been shown to be useful in the detection of subclinical joint inflammation in rheumatoid arthritis…
  • Abstract Number: 1753 • ACR Convergence 2023

    Acylcarnitine Enrichment Is a Characteristic of Rheumatoid Arthritis Fibroblast-Like Synoviocyte Metabolic Fingerprint

    Georgios Vasileiadis1, Anna-Karin Hultgård Ekwall2, Reshmi Sureshkumar1, Monica Guma3, Anna Rudin4, Yuan Zhang1 and Cristina Maglio1, 1Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, 2Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Kullavik, Sweden, 3San Diego VA Healthcare Service, La Jolla, CA, 4Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

    Background/Purpose: Several metabolic pathways have been implicated in rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) aggressive phenotype1,2. Here, we aimed to analyse the full spectrum of…
  • Abstract Number: 1819 • ACR Convergence 2023

    Clinical Indications Associated with New Opioid Use for Pain Management in the United Kingdom Using National Primary Care Data

    Max Lyon, Carlos Ramirez Medina, Elinor Davies and Meghna Jani, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom

    Background/Purpose: Prescription opioids for non-cancer pain in the UK have increased considerably over the past two decades, alongside a rise in associated harms. Despite the…
  • Abstract Number: 1631 • ACR Convergence 2023

    Comparison of Peripheral Biomarker Profiles Across Unique Multimorbidity Patterns in Rheumatoid Arthritis

    Chloe Peyton1, Tate Johnson1, Joshua Baker2, Yangyuna Yang1, Punyasha Roul1, Michael Duryee1, Jill Poole1, Geoffrey Thiele1, Ted R Mikuls3 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Rheumatoid arthritis (RA) predisposes affected individuals to develop multiple chronic conditions (i.e., multimorbidity). Mechanisms underlying multimorbidity onset in RA are incompletely understood, particularly for…
  • Abstract Number: 1015 • ACR Convergence 2023

    Health Care Access in an Indigenous North American Population of Rheumatoid Arthritis Patients and Their At-risk First-Degree Relatives

    Dana Wiens1, David Robinson1, Irene Smolik1, Cheryl Barnabe2, Hani El-Gabalawy1 and Liam O'Neil1, 1University of Manitoba, Winnipeg, MB, Canada, 2University of Calgary, Calgary, AB, Canada

    Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease that requires access to subspecialty care. Although Canada has a universal healthcare system, there are complex…
  • Abstract Number: 1040 • ACR Convergence 2023

    Impact of Ultrasound Limitation to Assess Aortitis in Patients with Giant Cell Arteritis: Comparative Study with FDG-PET/CT

    Juan Molina-Collada1, Isabel Castrejon2, Irene Monjo3, Elisa Fernandez-Fernandez4, Gabriela Torres5, JULIA MARTINEZ BARRIO6, Jose María Alvaro-Gracias7 and Eugenio De Miguel5, 1Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2Hospital Universitario Gregorio Marañón, Madrid, Spain, 3University Hospital La Paz, Madrid, Spain, 4La Paz University Hospital, Madrid, Spain, 5Hospital Universitario La Paz, Madrid, Spain, 6Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, 7Hospital General Universitario Gregorio Marañon, Madrid, Spain

    Background/Purpose: Aortitis is a serious potential complication of patients with giant cell arteritis (GCA) and may lead to dilation, aneurysms or dissection. Since ultrasound (US)…
  • Abstract Number: 1373 • ACR Convergence 2023

    Deltex1 May Involve the Function of T Regulatory Cells and Regulate the Disease Activity of Sjögren’s Syndrome

    Ming-Han Chen, Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

    Background/Purpose: Deltex1 is a transcription target of nuclear factor of activated T cells in mice and promotes T cell anergy. We have previously reported that…
  • Abstract Number: 1750 • ACR Convergence 2023

    Dysregulated NUB1 and Neddylation Enhances Rheumatoid Arthritis Fibroblast-Like Synoviocyte Inflammatory Responses

    Sho Sendo1, Camilla R. L. Machado2, Robert Benschop3, Narayanan B. Perumal4, Eunice Choi5, David Boyle5, Wei Wang5 and Gary Firestein2, 1Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 2University of California San Diego, San Diego, CA, 3Eli Lilly and Company, Indianapolis, IN, 4Eli Lilly and Company, San Diego, CA, 5University of California San Diego, La Jolla, CA

    Background/Purpose: Fibroblast-like synoviocytes (FLS) contribute to the pathogenesis of rheumatoid arthritis (RA), especially cartilage damage and cytokine production. These cells display an aggressive phenotype in…
  • Abstract Number: 1827 • ACR Convergence 2023

    Revolutionizing Fibromyalgia Treatment: Exploring the Efficacy of a New FDA Cleared Photoceutical Device

    Timothy Demchak1, Ernesto Leal-Junior2, Neide Ribeiro2, Heliodora Casalechi2, Douglas Johnson3 and Shaiane Tomazoni4, 1Indiana State University, Terre Haute, IN, 2Nove de Julho University, São Paulo, Brazil, 3Multi Radiance Medical, Solon, OH, 4University of Bergen, Bergen, Norway

    Background/Purpose: Fibromyalgia syndrome effects 2-8% of the general population and is characterized by specific tender points. FM annual economic impact $12-$14 billion.Current treatments are only…
  • Abstract Number: 1759 • ACR Convergence 2023

    Runx1 Is a Key Transcription Factor That Drives Synovial Fibroblast Pathogenicity in Rheumatoid Arthritis

    Christopher Mahony1, Samuel Kemble2, Paulynn Chin1, Cesar Prada3, Annie Hackland1, Patricia Reis-Nisa1, Lucy-Jayne Marsh1, Peter Keane1, Constanze Bonifer1, Christopher Buckley4, Stevephen Sansom5, Mark Coles4 and Adam Croft1, 1University of Birmingham, Birmingham, United Kingdom, 2University Birmingham, Rugeley, United Kingdom, 3The Kennedy Institute, Oxford, United Kingdom, 4University of Oxford, Oxford, United Kingdom, 5Kennedy Institute of Rheumatology, Oxford, United Kingdom

    Background/Purpose: Fibroblasts are key effector cells in rheumatoid arthritis (RA) underpinning joint inflammation and damage. Synovial tissue fibroblasts are heterogenous and acquire pathogenic cell states…
  • Abstract Number: 1633 • ACR Convergence 2023

    Dose Dependent Modulation of a B Cell Protein Signature by Ianalumab in Patients with Sjögren’s Disease

    Stephanie Finzel1, Andrea Grioni2, Benjamin A Fisher3, Athena S Papas4, Alexandre Avrameas2, Danny Tuckwell2, Jonas Zierer2, Celine Rauld2, Valeria De Luca2, Enrico Ferrero2, Andre Nogueira da Costa2, Rainer Hillenbrand2, Isabelle Isnardi2 and Wolfgang Hueber2, 1Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany, 2Novartis Pharma AG, Basel, Switzerland, 3University of Birmingham, Birmingham, United Kingdom, 4Division of Oral Medicine, Tufts School of Dental Medicine, Boston, MA

    Background/Purpose: Ianalumab (VAY736) is an afuscosylated monoclonal antibody targeting the B cell activating factor receptor (BAFFR) that depletes B cells via enhanced antibody dependent cellular…
  • « Previous Page
  • 1
  • …
  • 284
  • 285
  • 286
  • 287
  • 288
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology